We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock

Delisted

DCPH was delisted on the 10th of June, 2024.

177 hedge funds and large institutions have $944M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 67 increasing their positions, 53 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 14

26% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 53

8% more funds holding

Funds holding: 164177 (+13)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

3% less capital invested

Capital invested by funds: $972M → $944M (-$28.6M)

80% less call options, than puts

Call options by funds: $85K | Put options by funds: $434K

Holders
177
Holders Change
+13
Holders Change %
+7.93%
% of All Funds
2.55%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
27
Increased
67
Reduced
53
Closed
14
Calls
$85K
Puts
$434K
Net Calls
-$349K
Net Calls Change
-$898K
Name Holding Trade Value Shares
Change
Change in
Stake
VEA
101
Virtus ETF Advisers
New York
$379K +$53.3K +3,463 +17%
NYLIM
102
New York Life Investment Management
New York
$378K +$23.6K +1,535 +7%
Envestnet Asset Management
103
Envestnet Asset Management
Illinois
$375K +$46.6K +3,025 +15%
New York State Common Retirement Fund
104
New York State Common Retirement Fund
New York
$373K -$493 -32 -0.1%
EGM
105
Engineers Gate Manager
New York
$368K +$360K +23,377 New
Nisa Investment Advisors
106
Nisa Investment Advisors
Missouri
$362K +$954 +62 +0.3%
Capstone Investment Advisors
107
Capstone Investment Advisors
New York
$353K +$345K +22,421 New
Allspring Global Investments
108
Allspring Global Investments
North Carolina
$330K -$6.03K -392 -2%
YIH
109
Y-Intercept (HK)
Hong Kong
$320K +$313K +20,355 New
Fidelity Investments
110
Fidelity Investments
Massachusetts
$317K +$182K +11,842 +142%
BHCM
111
Brevan Howard Capital Management
Jersey
$295K -$87.8K -5,707 -23%
NIM
112
NEOS Investment Management
Connecticut
$293K +$8.44K +548 +3%
Los Angeles Capital Management
113
Los Angeles Capital Management
California
$291K +$285K +18,494 New
Wells Fargo
114
Wells Fargo
California
$282K +$35.8K +2,328 +15%
ETC
115
Exchange Traded Concepts
Oklahoma
$282K +$115K +7,462 +71%
EDRIA
116
Edmonds Duncan Registered Investment Advisors
Kansas
$279K
CIC
117
Cornercap Investment Counsel
Georgia
$262K
State Board of Administration of Florida Retirement System
118
State Board of Administration of Florida Retirement System
Florida
$257K +$24.2K +1,570 +10%
Principal Financial Group
119
Principal Financial Group
Iowa
$256K -$13.3K -865 -5%
CUAMC
120
China Universal Asset Management Company
China
$244K +$96.1K +6,241 +67%
T. Rowe Price Associates
121
T. Rowe Price Associates
Maryland
$242K +$30.5K +1,984 +15%
ProShare Advisors
122
ProShare Advisors
Maryland
$240K +$20K +1,299 +9%
Jane Street
123
Jane Street
New York
$232K -$1.18M -76,794 -84%
DTL
124
Dynamic Technology Lab
Singapore
$224K +$219K +14,257 New
Zurich Cantonal Bank
125
Zurich Cantonal Bank
Switzerland
$209K +$16.7K +1,088 +9%

DCPH Hedge Fund Activity: Q1 2024 in Review

177 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q1 2024, worth a combined $944M — down 2.9% from $972M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new DCPH positions and 14 closed out — a net gain of 13 holders — while 67 added to existing stakes and 53 trimmed.

The largest buyer was Armistice Capital, adding an estimated $10.8M. The largest seller was Morgan Stanley, cutting an estimated $47.6M.

  • 177 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q1 2024, up from 164 in Q4 2023.
  • Funds reported $944M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q1 2024, down 2.9% quarter-over-quarter.
  • 27 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q1 2024 and 14 closed out, a net change of +13 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q1 2024 was Armistice Capital, an estimated $10.8M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q1 2024 was Morgan Stanley, an estimated $47.6M sold.

Based on aggregated 13F filings for Q1 2024.